Twice-yearly HIV prevention shot raises access equity questions

A twice-yearly injectable HIV prevention drug, described as the closest thing to an HIV vaccine, has been developed, but the article focuses on the unresolved question of who will gain access. The core claim is the drug's existence and efficacy, which is not fully detailed, while the access debate is the central theme. This matters because equitable distribution will determine the global impact on HIV incidence.